SCHEMBL4291980

SCHEMBL4291980

CC1(C)OB(c2cc3cc(C(F)(F)F)ccc3s2)OC1(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.39
KDR P35968 3/20 0.39
CHRNA7 P36544 1/20 0.35
HTR3A P46098 1/20 0.35
DYRK1A Q13627 2/20 0.34
EPHX2 P34913 1/20 0.34
SCN4A P35499 1/20 0.34
CLK1 P49759 1/20 0.32
ILK Q13418 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
ACE2 Q9BYF1 1/20 0.31
CYBB P04839 1/20 0.31
NOX3 Q9HBY0 1/20 0.31
NOX4 Q9NPH5 1/20 0.31
NOX1 Q9Y5S8 1/20 0.31
SNCA P37840 1/20 0.30
LPL P06858 2/20 0.30
LIPG Q9Y5X9 2/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18002998 0.82 CHRNA7 (0.35) PDGFRBKDRCHRNA7HTR3ADYRK1A
SCHEMBL16010464 0.81 LPL (0.42) PDGFRBKDRCHRNA7HTR3ACLK1
SCHEMBL1231936 0.80 NPC1 (0.38) DYRK1ASCN4ACLK1HDAC6SNCA
SCHEMBL13721705 0.78 MAPK1 (0.34) SNCALPLLIPG
SCHEMBL17669989 0.78 PDGFRB (0.35) PDGFRBKDRCHRNA7CLK1SNCA
SCHEMBL25234076 0.75 NPC1 (0.35) PDGFRBKDRSCN4AHDAC6SNCA
SCHEMBL30457570 0.75 NPC1 (0.35) PDGFRBKDRSCN4AHDAC6SNCA
SCHEMBL119228 0.75 LPL (0.44) HDAC6LPLLIPG
SCHEMBL20984011 0.74 LIPG (0.51) PDGFRBKDRSNCALPLLIPG
SCHEMBL4339028 0.74 CYP2A6 (0.41) PDGFRBKDRSNCALPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598202-B2 Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA NV (BE) 2013-12-03 US disclosed
EP-2254415-B1 ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2013-01-23 EP disclosed
EP-2254415-B1 ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2013-01-23 EP disclosed
US-20090264429-A1 Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2009-10-22 US disclosed
US-20090264429-A1 Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2009-10-22 US disclosed
US-20090264429-A1 Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264429-A1 Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase FAAH, FAAH2, HRH2 PDGFRB 619/4885KDR 4223/4885CHRNA7 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.